Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer

Nuclear Medicine Communications

Volumn 32, Issue 6, 2011, Pages 475-478

  Castellucci, Paolo ^a   Fuccio, Chiara ^a   Marzola, Maria Cristina ^b   Al Nahhas, Adil ^c   Rubello, Domenico ^b   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Choline positron emission tomography computerized tomography; early biochemical relapse; prostate cancer; prostate specific antigen kinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN;

BIOCHEMICAL RELAPSE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RELAPSE; CANCER SURGERY; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; KINETICS; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

CHOLINE; HUMANS; KINETICS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79955563898     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283455765     Document Type: Review

References (24)

1. ESMO Guidelines Task Force. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann Oncol 2005; 16 (Suppl 1):i34-i36.
2. Fanti S, Nanni C, Ambrosini V, Gross MD, Rubello D, Farsad M. PET in genitourinary tract cancers. Q J Nucl Med Mol Imaging 2007; 51:260-271. (Pubitemid 47189064)
3. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J NuclMed 2008; 49:2031-2041.
4. Naya Y, Okihara K, Evans RB, Babaian RJ. Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy. Urology 2005; 66:350-355. (Pubitemid 41138096)
5. Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol 2008; 179:906-910.
6. Cher ML, Bianco FJ Jr, Lam JS, Davis LP, Grignon DJ, SakrWA, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998; 160:1387-1391. (Pubitemid 29480523)
7. Gomez P, Manoharan M, Kim SS, Soloway MS. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int 2004; 94:299-302. (Pubitemid 39120167)
8. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, DeKernion JB, et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004; 171:2260.
9. Phelps ME. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA 2000; 97:9226-9233. (Pubitemid 30627544)
10. Schoder H, Herrmann K, Gonen M, Hricak H, Eberhard S, Scardino P, et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005; 11:4761-4769. (Pubitemid 41557196)
11. Sandblom G, Sorensen J, Lundin N, Haggman M, Malmstrom PU. Positron patients with prostate-specific antigen relapse after radical prostatectomy. Urology 2006; 67:996-1000.
12. Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA, Katzenellenbogen JA, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005; 32:344-350. (Pubitemid 40562127)
13. Tó th G, Lengyel Z, Balkay L, Salah MA, Trón L,Tó th C. Detection of prostate cancer with 11C-methionine positron emission tomography. J Urol 2005; 173:66-69. (Pubitemid 39627673)
14. Maecke HR, Hofmann M, Haberkorn U. [68]Ga-labeled peptides in tumor imaging. J Nucl Med 2005; 46:172S-178S.
15. Zeisel SH. Dietary Choline: biochemistry, physiology and pharmacology. Ann Rev Nutr 1981; 1:95-121.
16. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucosepositron emission tomography. J Urol 2003; 169:1337-1340. (Pubitemid 36323779)
17. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [(11)C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35:18-23. (Pubitemid 350234152)
18. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010; 37:301-309.
19. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009; 50:1394-1400.
20. Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, et al. PSA doubling time for prediction of 11C-choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010; 37:1106-1116.
21. Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, et al. Is there a role for (11)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging 2011; 38:55-63
22. Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S. Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol ; in press. Online 25 August 2010. PMID: 20800404. doi:10.1016/j.ejrad.2010.07.023.
23. Picchio M, Giovannini E, Crivellaro C, Gianolli L, Di Muzio N, Messa C. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. Radiother Oncol 2010; 96:347-350.
24. Cochet A, Rousseau C, Dewas S, Supiot S, Brunotte F, Truc G, et al. Fluorocholine(18F) (FCH) PET/CT for guiding image-guided salvage intensity-modulated radiation therapy (IG-sIMRT) in occult recurrence of prostate cancer: initial experience. J Nucl Med 2010; 37:336.